{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:51:13Z","timestamp":1791327073443,"version":"4.3.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","award":["Innovation Ecosystem Heal Italia PE00000019"],"award-info":[{"award-number":["Innovation Ecosystem Heal Italia PE00000019"]}],"id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","award":["Innovation Ecosystem Rome Technopole ECS00000024"],"award-info":[{"award-number":["Innovation Ecosystem Rome Technopole ECS00000024"]}],"id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","award":["Innovation Ecosystem Rome Technopole ECS00000024"],"award-info":[{"award-number":["Innovation Ecosystem Rome Technopole ECS00000024"]}],"id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","award":["Innovation Ecosystem Heal Italia PE00000019"],"award-info":[{"award-number":["Innovation Ecosystem Heal Italia PE00000019"]}],"id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","award":["Innovation Ecosystem Rome Technopole ECS00000024"],"award-info":[{"award-number":["Innovation Ecosystem Rome Technopole ECS00000024"]}],"id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["IG 21366"],"award-info":[{"award-number":["IG 21366"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["IG 21366"],"award-info":[{"award-number":["IG 21366"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["IG 21366"],"award-info":[{"award-number":["IG 21366"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["IG 21366"],"award-info":[{"award-number":["IG 21366"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>IL-33 is an epithelial-derived alarmin with various roles in cancer. In melanoma, endogenous and exogenous IL-33 exert anti-tumor effects through the stimulation of several immune effector cells. In this study, we explored the combination of IL- 33 with Decitabine (DAC), a DNA methylation inhibitor that promotes immune recognition by re-activating silenced genes, for melanoma treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Multicellular spheroids, organ-on-chip technology and in vivo models were used to test the anti-tumor effects of IL-33 combined with DAC against mouse and human melanoma. Mice deficient for the IL-33 receptor ST2 (ST2<jats:sup>\u2212\/\u2212<\/jats:sup> mice) were employed to address the role of endogenous IL-33 signaling in DAC therapeutic response and tumor-immune crosstalk.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In multicellular spheroids of mouse and human melanoma cells, DAC alone inhibited tumor cell aggregation, suggesting its direct effect on tumor cells. In vivo, DAC combined with IL-33 reduced tumor growth and prolonged the survival of mice transplanted with melanoma cells, outperforming single treatments. Moreover, the combined DAC\/IL-33 treatment was the most efficient in promoting immune recruitment (i.e., T cells and eosinophils) at the tumor site and induced the up-regulation of PD-1 resulting in better therapeutic response to PD-1 blockade in vivo. In a microfluidic-based competitive migration assay, DAC\/IL- 33 treatment generated the strongest chemotactic response, attracting spleen cells from na\u00efve wild-type, but not ST2<jats:sup>\u2212\/\u2212<\/jats:sup> mice, indicating that IL-33 signaling was crucial for immune cell recruitment. Accordingly, DAC failed to induce tumor immune infiltration and was ineffective in reducing tumor growth in ST2<jats:sup>\u2212\/\u2212<\/jats:sup> mice. In vivo, DAC increased the expression of ST2 and IL-33 at the tumor site, suggesting it may enhance endogenous IL-33 production. Methylation studies indicated that DAC increased the expression of IL-33 in mouse and human melanoma cells through demethylation of a transcription factor binding site located inside the <jats:italic>IL33<\/jats:italic> gene.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our findings indicate that DAC effectively co-operates with IL-33\/ST2 axis against melanoma through immune cell recruitment and epigenetic regulation of gene expression, thus remodeling the tumor immune microenvironment to overcome resistance to PD- 1 inhibition.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13046-025-03381-z","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T17:38:38Z","timestamp":1746207518000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Decitabine co-operates with the IL-33\/ST2 axis modifying the tumor microenvironment and improving the response to PD-1 blockade in melanoma"],"prefix":"10.1186","volume":"44","author":[{"given":"Francesco","family":"Noto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Rosa","family":"Gambardella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Curcio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"De Ninno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Andreone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Buccione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"D\u2019Urso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Macchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Pacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Spada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Businaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Afferni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Mattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Schiavoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"3381_CR1","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.3389\/fimmu.2018.02601","volume":"9","author":"C Afferni","year":"2018","unstructured":"Afferni C, Buccione C, Andreone S, Galdiero MR, Varricchi G, Marone G, et al. The pleiotropic immunomodulatory functions of IL-33 and its implications in tumor immunity. Front Immunol. 2018;9:2601. https:\/\/doi.org\/10.3389\/fimmu.2018.02601.","journal-title":"Front Immunol"},{"key":"3381_CR2","doi-asserted-by":"publisher","first-page":"571593","DOI":"10.3389\/fimmu.2020.571593","volume":"11","author":"S Andreone","year":"2020","unstructured":"Andreone S, Gambardella AR, Mancini J, Loffredo S, Marcella S, La Sorsa V, et al. Anti-tumorigenic activities of IL-33: a mechanistic insight. Front Immunol. 2020;11:571593. https:\/\/doi.org\/10.3389\/fimmu.2020.571593.","journal-title":"Front Immunol"},{"key":"3381_CR3","doi-asserted-by":"publisher","unstructured":"Andreone S, Spadaro F, Buccione C, Mancini J, Tinari A, Sestili P, et al. IL-33 promotes CD11b\/CD18-mediated adhesion of eosinophils to cancer cells and synapse-polarized degranulation leading to tumor cell killing. Cancers (Basel). 2019;11(11). https:\/\/doi.org\/10.3390\/cancers11111664.","DOI":"10.3390\/cancers11111664"},{"key":"3381_CR4","doi-asserted-by":"publisher","unstructured":"Lucarini V, Ziccheddu G, Macchia I, La Sorsa V, Peschiaroli F, Buccione C, et al. IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils. OncoImmunology. 2017;6(6). https:\/\/doi.org\/10.1080\/2162402X.2017.1317420.","DOI":"10.1080\/2162402X.2017.1317420"},{"issue":"3","key":"3381_CR5","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.4049\/jimmunol.1501399","volume":"198","author":"D Dominguez","year":"2017","unstructured":"Dominguez D, Ye C, Geng Z, Chen S, Fan J, Qin L, et al. Exogenous IL-33 restores dendritic cell activation and maturation in established cancer. J Immunol. 2017;198(3):1365\u201375. https:\/\/doi.org\/10.4049\/jimmunol.1501399.","journal-title":"J Immunol"},{"issue":"1","key":"3381_CR6","doi-asserted-by":"publisher","first-page":"438","DOI":"10.4049\/jimmunol.1401344","volume":"194","author":"X Gao","year":"2015","unstructured":"Gao X, Wang X, Yang Q, Zhao X, Wen W, Li G, et al. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. J Immunol. 2015;194(1):438\u201345. https:\/\/doi.org\/10.4049\/jimmunol.1401344.","journal-title":"J Immunol"},{"issue":"5","key":"3381_CR7","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.4049\/jimmunol.1501730","volume":"196","author":"J Kim","year":"2016","unstructured":"Kim J, Kim W, Moon UJ, Kim HJ, Choi HJ, Sin JI, et al. Intratumorally establishing type 2 innate lymphoid cells blocks tumor growth. J Immunol. 2016;196(5):2410\u201323. https:\/\/doi.org\/10.4049\/jimmunol.1501730.","journal-title":"J Immunol"},{"key":"3381_CR8","doi-asserted-by":"publisher","first-page":"155961","DOI":"10.1016\/j.cyto.2022.155961","volume":"157","author":"WJ Yeoh","year":"2022","unstructured":"Yeoh WJ, Vu VP, Krebs P. IL-33 biology in cancer: an update and future perspectives. Cytokine. 2022;157:155961. https:\/\/doi.org\/10.1016\/j.cyto.2022.155961.","journal-title":"Cytokine"},{"issue":"11","key":"3381_CR9","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1158\/2326-6066.CIR-19-1024","volume":"8","author":"L Chen","year":"2020","unstructured":"Chen L, Sun R, Xu J, Zhai W, Zhang D, Yang M, et al. Tumor-derived IL33 promotes tissue-resident CD8+ T cells and is required for checkpoint blockade tumor immunotherapy. Cancer Immunol Res. 2020;8(11):1381\u201392. https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-1024.","journal-title":"Cancer Immunol Res"},{"key":"3381_CR10","doi-asserted-by":"publisher","unstructured":"Dixit A, Sarver A, Zettervall J, Huang H, Zheng K, Brekken RA, et al. Targeting TNF-\u03b1-producing macrophages activates antitumor immunity in pancreatic cancer via IL-33 signaling. JCI Insight. 2022;7(22). https:\/\/doi.org\/10.1172\/jci.insight.153242.","DOI":"10.1172\/jci.insight.153242"},{"issue":"1","key":"3381_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ccell.2022.11.014","volume":"41","author":"OS Blomberg","year":"2023","unstructured":"Blomberg OS, Spagnuolo L, Garner H, Voorwerk L, Isaeva OI, van Dyk E, et al. IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer. Cancer Cell. 2023;41(1):106\u201323.e10. https:\/\/doi.org\/10.1016\/j.ccell.2022.11.014.","journal-title":"Cancer Cell"},{"issue":"3","key":"3381_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41590-019-0321-5","volume":"20","author":"C Hollande","year":"2019","unstructured":"Hollande C, Boussier J, Ziai J, Nozawa T, Bondet V, Phung W, et al. Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth. Nat Immunol. 2019;20(3):257\u201364. https:\/\/doi.org\/10.1038\/s41590-019-0321-5.","journal-title":"Nat Immunol"},{"issue":"7","key":"3381_CR13","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/s41590-021-00943-z","volume":"22","author":"N Jacquelot","year":"2021","unstructured":"Jacquelot N, Seillet C, Wang M, Pizzolla A, Liao Y, Hediyeh-Zadeh S, et al. Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma. Nat Immunol. 2021;22(7):851\u201364. https:\/\/doi.org\/10.1038\/s41590-021-00943-z.","journal-title":"Nat Immunol"},{"key":"3381_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2015-4","author":"JA Moral","year":"2020","unstructured":"Moral JA, Leung J, Rojas LA, Ruan J, Zhao J, Sethna Z, et al. ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature. 2020. https:\/\/doi.org\/10.1038\/s41586-020-2015-4.","journal-title":"Nature"},{"key":"3381_CR15","doi-asserted-by":"publisher","unstructured":"Giunta EF, Arrichiello G, Curvietto M, Pappalardo A, Bosso D, Rosanova M, et al. Epigenetic regulation in melanoma: facts and hopes. Cells. 2021;10(8). https:\/\/doi.org\/10.3390\/cells10082048.","DOI":"10.3390\/cells10082048"},{"key":"3381_CR16","doi-asserted-by":"publisher","unstructured":"Gracia-Hernandez M, Munoz Z, Villagra A. Enhancing therapeutic approaches for melanoma patients targeting epigenetic modifiers. Cancers (Basel). 2021;13(24). https:\/\/doi.org\/10.3390\/cancers13246180.","DOI":"10.3390\/cancers13246180"},{"key":"3381_CR17","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.3389\/fphar.2018.01443","volume":"9","author":"C Fazio","year":"2018","unstructured":"Fazio C, Covre A, Cutaia O, Lofiego MF, Tunici P, Chiarucci C, et al. Immunomodulatory properties of DNA hypomethylating agents: selecting the optimal epigenetic partner for cancer immunotherapy. Front Pharmacol. 2018;9:1443. https:\/\/doi.org\/10.3389\/fphar.2018.01443.","journal-title":"Front Pharmacol"},{"key":"3381_CR18","doi-asserted-by":"publisher","first-page":"106971","DOI":"10.1016\/j.intimp.2020.106971","volume":"88","author":"J Han","year":"2020","unstructured":"Han J, Xu X, Liu Z, Li Z, Wu Y, Zuo D. Recent advances of molecular mechanisms of regulating PD-L1 expression in melanoma. Int Immunopharmacol. 2020;88:106971. https:\/\/doi.org\/10.1016\/j.intimp.2020.106971.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"3381_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13046-023-02628-x","volume":"42","author":"A Amaro","year":"2023","unstructured":"Amaro A, Reggiani F, Fenoglio D, Gangemi R, Tosi A, Parodi A, et al. Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells. J Exp Clin Cancer Res. 2023;42(1):67. https:\/\/doi.org\/10.1186\/s13046-023-02628-x.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"3381_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jid.2016.08.024","volume":"137","author":"V Lucarini","year":"2017","unstructured":"Lucarini V, Buccione C, Ziccheddu G, Peschiaroli F, Sestili P, Puglisi R, et al. Combining type I interferons and 5-Aza-2?-deoxycitidine to improve anti-tumor response against melanoma. J Investig Dermatol. 2017;137(1):159\u201369. https:\/\/doi.org\/10.1016\/j.jid.2016.08.024.","journal-title":"J Investig Dermatol"},{"issue":"7","key":"3381_CR21","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00262-015-1776-3","volume":"65","author":"MH Saleh","year":"2016","unstructured":"Saleh MH, Wang L, Goldberg MS. Improving cancer immunotherapy with DNA methyltransferase inhibitors. Cancer Immunol Immunother. 2016;65(7):787\u201396. https:\/\/doi.org\/10.1007\/s00262-015-1776-3.","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"3381_CR22","first-page":"3124","volume":"9","author":"K Kozar","year":"2003","unstructured":"Kozar K, Kami\u0144ski R, Switaj T, O\u0142dak T, Machaj E, Wysocki PJ, et al. Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2\u2019-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice. Clin Cancer Res. 2003;9(8):3124\u201333.","journal-title":"Clin Cancer Res"},{"key":"3381_CR23","doi-asserted-by":"publisher","unstructured":"Zhang P, Tao C, Lu Y, Li P, Wang X, Dai Y, et al. Epigenetic reprogramming potentiates ICAM1 antibody drug conjugates in preclinical models of melanoma. Adv Sci (Weinh). 2024;11(30). https:\/\/doi.org\/10.1002\/advs.202400203.","DOI":"10.1002\/advs.202400203"},{"key":"3381_CR24","doi-asserted-by":"publisher","first-page":"1074644","DOI":"10.3389\/fimmu.2022.1074644","volume":"13","author":"JT Gordy","year":"2022","unstructured":"Gordy JT, Sandhu AK, Fessler K, Luo K, Kapoor AR, Ayeh SK, et al. IFN\u03b1 and 5-Aza-2\u2019-deoxycytidine combined with a dendritic-cell targeting DNA vaccine alter tumor immune cell infiltration in the B16F10 melanoma model. Front Immunol. 2022;13:1074644. https:\/\/doi.org\/10.3389\/fimmu.2022.1074644.","journal-title":"Front Immunol"},{"issue":"4","key":"3381_CR25","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00262-019-02471-0","volume":"69","author":"JT Gordy","year":"2020","unstructured":"Gordy JT, Luo K, Kapoor A, Kim ES, Ayeh SK, Karakousis PC, et al. Treatment with an immature dendritic cell-targeting vaccine supplemented with IFN-\u03b1 and an inhibitor of DNA methylation markedly enhances survival in a murine melanoma model. Cancer Immunol Immunother. 2020;69(4):569\u201380. https:\/\/doi.org\/10.1007\/s00262-019-02471-0.","journal-title":"Cancer Immunol Immunother"},{"key":"3381_CR26","doi-asserted-by":"publisher","unstructured":"De Ninno A, Bertani FR, Gerardino A, Schiavoni G, Musella M, Galassi C, et al. Microfluidic co-culture models for dissecting the immune response in in vitro tumor microenvironments. J Vis Exp. 2021(170). https:\/\/doi.org\/10.3791\/61895.","DOI":"10.3791\/61895"},{"issue":"9","key":"3381_CR27","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/s41590-019-0441-y","volume":"20","author":"V Verma","year":"2019","unstructured":"Verma V, Shrimali RK, Ahmad S, Dai W, Wang H, Lu S, et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1. Nat Immunol. 2019;20(9):1231\u201343. https:\/\/doi.org\/10.1038\/s41590-019-0441-y.","journal-title":"Nat Immunol"},{"key":"3381_CR28","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/bs.mie.2019.06.012","volume":"632","author":"A Mencattini","year":"2020","unstructured":"Mencattini A, De Ninno A, Mancini J, Businaro L, Martinelli E, Schiavoni G, et al. High-throughput analysis of cell-cell crosstalk in ad hoc designed microfluidic chips for oncoimmunology applications. Methods Enzymol. 2020;632:479\u2013502. https:\/\/doi.org\/10.1016\/bs.mie.2019.06.012.","journal-title":"Methods Enzymol"},{"key":"3381_CR29","doi-asserted-by":"publisher","first-page":"627454","DOI":"10.3389\/fmolb.2021.627454","volume":"8","author":"F Mattei","year":"2021","unstructured":"Mattei F, Andreone S, Mencattini A, De Ninno A, Businaro L, Martinelli E, et al. Oncoimmunology meets organs-on-chip. Front Mol Biosci. 2021;8:627454. https:\/\/doi.org\/10.3389\/fmolb.2021.627454.","journal-title":"Front Mol Biosci"},{"issue":"3","key":"3381_CR30","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/pcmr.12926","volume":"34","author":"GH Attrill","year":"2021","unstructured":"Attrill GH, Ferguson PM, Palendira U, Long GV, Wilmott JS, Scolyer RA. The tumour immune landscape and its implications in cutaneous melanoma. Pigment Cell Melanoma Res. 2021;34(3):529\u201349. https:\/\/doi.org\/10.1111\/pcmr.12926.","journal-title":"Pigment Cell Melanoma Res"},{"key":"3381_CR31","doi-asserted-by":"publisher","unstructured":"Knight A, Karapetyan L, Kirkwood JM. Immunotherapy in melanoma: recent advances and future directions. Cancers (Basel). 2023;15(4). https:\/\/doi.org\/10.3390\/cancers15041106.","DOI":"10.3390\/cancers15041106"},{"key":"3381_CR32","doi-asserted-by":"publisher","unstructured":"Simiczyjew A, Dratkiewicz E, Mazurkiewicz J, Zi\u0119tek M, Matkowski R, Nowak D. The influence of tumor microenvironment on immune escape of melanoma. Int J Mol Sci. 2020;21(21). https:\/\/doi.org\/10.3390\/ijms21218359.","DOI":"10.3390\/ijms21218359"},{"issue":"2","key":"3381_CR33","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.canlet.2013.03.002","volume":"335","author":"K Gao","year":"2013","unstructured":"Gao K, Li X, Zhang L, Bai L, Dong W, Shi G, et al. Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice. Cancer Lett. 2013;335(2):463\u201371. https:\/\/doi.org\/10.1016\/j.canlet.2013.03.002.","journal-title":"Cancer Lett"},{"issue":"6","key":"3381_CR34","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1158\/0008-5472.CAN-13-2729","volume":"74","author":"DO Villarreal","year":"2014","unstructured":"Villarreal DO, Wise MC, Walters JN, Reuschel EL, Choi MJ, Obeng-Adjei N, et al. Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res. 2014;74(6):1789\u2013800. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-2729.","journal-title":"Cancer Res"},{"issue":"1","key":"3381_CR35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s13046-024-03129-1","volume":"43","author":"AR Gambardella","year":"2024","unstructured":"Gambardella AR, Antonucci C, Zanetti C, Noto F, Andreone S, Vacca D, et al. IL-33 stimulates the anticancer activities of eosinophils through extracellular vesicle-driven reprogramming of tumor cells. J Exp Clin Cancer Res. 2024;43(1):209. https:\/\/doi.org\/10.1186\/s13046-024-03129-1.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"3381_CR36","doi-asserted-by":"publisher","first-page":"703","DOI":"10.4049\/jimmunol.1101270","volume":"188","author":"M Ikutani","year":"2012","unstructured":"Ikutani M, Yanagibashi T, Ogasawara M, Tsuneyama K, Yamamoto S, Hattori Y, et al. Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity. J Immunol. 2012;188(2):703\u201313. https:\/\/doi.org\/10.4049\/jimmunol.1101270.","journal-title":"J Immunol"},{"key":"3381_CR37","doi-asserted-by":"publisher","unstructured":"Kienzl M, Hasenoehrl C, Valadez-Cosmes P, Maitz K, Sarsembayeva A, Sturm E, et al. IL-33 reduces tumor growth in models of colorectal cancer with the help of eosinophils. Oncoimmunology. 2020;9(1). https:\/\/doi.org\/10.1080\/2162402X.2020.1776059.","DOI":"10.1080\/2162402X.2020.1776059"},{"key":"3381_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-3-030-35723-8_2","volume":"1224","author":"G Marone","year":"2020","unstructured":"Marone G, Gambardella AR, Mattei F, Mancini J, Schiavoni G, Varricchi G. Basophils in tumor microenvironment and surroundings. Adv Exp Med Biol. 2020;1224:21\u201334. https:\/\/doi.org\/10.1007\/978-3-030-35723-8_2.","journal-title":"Adv Exp Med Biol"},{"issue":"8","key":"3381_CR39","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1016\/j.celrep.2020.01.103","volume":"30","author":"M Wagner","year":"2020","unstructured":"Wagner M, Ealey KN, Tetsu H, Kiniwa T, Motomura Y, Moro K, et al. Tumor-derived lactic acid contributes to the paucity of intratumoral ILC2s. Cell Rep. 2020;30(8):2743\u201357.e5. https:\/\/doi.org\/10.1016\/j.celrep.2020.01.103.","journal-title":"Cell Rep"},{"issue":"6","key":"3381_CR40","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1046\/j.1523-1747.2002.01725.x","volume":"118","author":"AS Payne","year":"2002","unstructured":"Payne AS, Cornelius LA. The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol. 2002;118(6):915\u201322. https:\/\/doi.org\/10.1046\/j.1523-1747.2002.01725.x.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"3381_CR41","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/ni.3159","volume":"16","author":"R Carretero","year":"2015","unstructured":"Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, H\u00e4mmerling GJ. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol. 2015;16(6):609\u201317. https:\/\/doi.org\/10.1038\/ni.3159.","journal-title":"Nat Immunol"},{"key":"3381_CR42","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.molimm.2017.04.012","volume":"87","author":"J Dunn","year":"2017","unstructured":"Dunn J, Rao S. Epigenetics and immunotherapy: the current state of play. Mol Immunol. 2017;87:227\u201339. https:\/\/doi.org\/10.1016\/j.molimm.2017.04.012.","journal-title":"Mol Immunol"},{"issue":"4","key":"3381_CR43","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41423-018-0026-y","volume":"16","author":"G Yu","year":"2019","unstructured":"Yu G, Wu Y, Wang W, Xu J, Lv X, Cao X, et al. Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment. Cell Mol Immunol. 2019;16(4):401\u20139. https:\/\/doi.org\/10.1038\/s41423-018-0026-y.","journal-title":"Cell Mol Immunol"},{"key":"3381_CR44","doi-asserted-by":"publisher","unstructured":"Huang KC, Chiang SF, Chen WT, Chen TW, Hu CH, Yang PC, et al. Decitabine augments chemotherapy-induced PD-L1 upregulation for PD-L1 blockade in colorectal cancer. Cancers (Basel). 2020;12(2). https:\/\/doi.org\/10.3390\/cancers12020462.","DOI":"10.3390\/cancers12020462"},{"key":"3381_CR45","doi-asserted-by":"publisher","unstructured":"Li X, Li Y, Dong L, Chang Y, Zhang X, Wang C, et al. Decitabine priming increases anti-PD-1 antitumor efficacy by promoting CD8+ progenitor exhausted T cell expansion in tumor models. J Clin Invest. 2023;133(7). https:\/\/doi.org\/10.1172\/JCI165673.","DOI":"10.1172\/JCI165673"},{"issue":"21","key":"3381_CR46","doi-asserted-by":"publisher","first-page":"4754","DOI":"10.1158\/0008-5472.CAN-20-0285","volume":"80","author":"TA Gonda","year":"2020","unstructured":"Gonda TA, Fang J, Salas M, Do C, Hsu E, Zhukovskaya A, et al. A DNA hypomethylating drug alters the tumor microenvironment and improves the effectiveness of immune checkpoint inhibitors in a mouse model of pancreatic cancer. Cancer Res. 2020;80(21):4754\u201367. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-0285.","journal-title":"Cancer Res"},{"issue":"3","key":"3381_CR47","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/BF00269027","volume":"13","author":"RL Momparler","year":"1984","unstructured":"Momparler RL, Samson J, Momparler LF, Rivard GE. Cell cycle effects and cellular pharmacology of 5-aza-2\u2019-deoxycytidine. Cancer Chemother Pharmacol. 1984;13(3):191\u20134. https:\/\/doi.org\/10.1007\/BF00269027.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"38","key":"3381_CR48","doi-asserted-by":"publisher","first-page":"61069","DOI":"10.18632\/oncotarget.11179","volume":"7","author":"L Qin","year":"2016","unstructured":"Qin L, Dominguez D, Chen S, Fan J, Long A, Zhang M, et al. Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia. Oncotarget. 2016;7(38):61069\u201380. https:\/\/doi.org\/10.18632\/oncotarget.11179.","journal-title":"Oncotarget"},{"issue":"4","key":"3381_CR49","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00262-023-03580-7","volume":"73","author":"J Yue","year":"2024","unstructured":"Yue J, Guo H, Xu P, Ma J, Shi W, Wu Y. Combination of IL-33 with PD-1 blockade augment mILC2s-mediated anti-tumor immunity. Cancer Immunol Immunother. 2024;73(4):65. https:\/\/doi.org\/10.1007\/s00262-023-03580-7.","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"3381_CR50","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.4049\/jimmunol.1800627","volume":"201","author":"Z Jin","year":"2018","unstructured":"Jin Z, Lei L, Lin D, Liu Y, Song Y, Gong H, et al. IL-33 released in the liver inhibits tumor growth via promotion of CD4+ and CD8+ T cell responses in hepatocellular carcinoma. J Immunol. 2018;201(12):3770\u20139. https:\/\/doi.org\/10.4049\/jimmunol.1800627.","journal-title":"J Immunol"},{"key":"3381_CR51","doi-asserted-by":"publisher","first-page":"15327","DOI":"10.1038\/ncomms15327","volume":"8","author":"SM Kallert","year":"2017","unstructured":"Kallert SM, Darbre S, Bonilla WV, Kreutzfeldt M, Page N, M\u00fcller P, et al. Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy. Nat Commun. 2017;8:15327. https:\/\/doi.org\/10.1038\/ncomms15327.","journal-title":"Nat Commun"},{"issue":"2","key":"3381_CR52","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.bbrc.2019.08.058","volume":"518","author":"Y Xia","year":"2019","unstructured":"Xia Y, Ohno T, Nishii N, Bhingare A, Tachinami H, Kashima Y, et al. Endogenous IL-33 exerts CD8(+) T cell antitumor responses overcomingpro-tumor effects by regulatory T cells in a colon carcinoma model. BiochemBiophys Res Commun. 2019;518(2):331\u20136. https:\/\/doi.org\/10.1016\/j.bbrc.2019.08.058.","journal-title":"BiochemBiophys Res Commun"},{"key":"3381_CR53","doi-asserted-by":"publisher","first-page":"8327","DOI":"10.1038\/ncomms9327","volume":"6","author":"ES Cohen","year":"2015","unstructured":"Cohen ES, Scott IC, Majithiya JB, Rapley L, Kemp BP, England E, et al. Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation. Nat Commun. 2015;6:8327. https:\/\/doi.org\/10.1038\/ncomms9327.","journal-title":"Nat Commun"},{"issue":"22","key":"3381_CR54","doi-asserted-by":"publisher","first-page":"9021","DOI":"10.1073\/pnas.0812690106","volume":"106","author":"C Cayrol","year":"2009","unstructured":"Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A. 2009;106(22):9021\u20136. https:\/\/doi.org\/10.1073\/pnas.0812690106.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"3381_CR55","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/imr.12619","volume":"281","author":"C Cayrol","year":"2018","unstructured":"Cayrol C, Girard JP. Interleukin-33 (IL-33): a nuclear cytokine from the IL-1 family. Immunol Rev. 2018;281(1):154\u201368. https:\/\/doi.org\/10.1111\/imr.12619.","journal-title":"Immunol Rev"},{"issue":"1","key":"3381_CR56","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12948-021-00157-6","volume":"19","author":"E Di Salvo","year":"2021","unstructured":"Di Salvo E, Casciaro M, Gangemi S. IL-33 genetics and epigenetics in immune-related diseases. Clin Mol Allergy. 2021;19(1):18. https:\/\/doi.org\/10.1186\/s12948-021-00157-6.","journal-title":"Clin Mol Allergy"},{"issue":"5","key":"3381_CR57","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/acn3.47","volume":"1","author":"F Zhang","year":"2014","unstructured":"Zhang F, Tossberg JT, Spurlock CF, Yao SY, Aune TM, Sriram S. Expression of IL-33 and its epigenetic regulation in multiple sclerosis. Ann Clin Transl Neurol. 2014;1(5):307\u201318. https:\/\/doi.org\/10.1002\/acn3.47.","journal-title":"Ann Clin Transl Neurol"},{"key":"3381_CR58","doi-asserted-by":"publisher","first-page":"1114699","DOI":"10.3389\/fimmu.2023.1114699","volume":"14","author":"CH Luo","year":"2023","unstructured":"Luo CH, Lai AC, Chang YJ. Butyrate inhibits Staphylococcus aureus-aggravated dermal IL-33 expression and skin inflammation through histone deacetylase inhibition. Front Immunol. 2023;14:1114699. https:\/\/doi.org\/10.3389\/fimmu.2023.1114699.","journal-title":"Front Immunol"},{"issue":"1","key":"3381_CR59","first-page":"64","volume":"19","author":"A Pishdadian","year":"2016","unstructured":"Pishdadian A, Varasteh A, Gholamin M, Nasiraie LR, Hosseinpour M, Moghadam M, et al. Lung-derived innate cytokines: new epigenetic targets of allergen-specific sublingual immunotherapy. Iran J Basic Med Sci. 2016;19(1):64\u201371.","journal-title":"Iran J Basic Med Sci"},{"key":"3381_CR60","doi-asserted-by":"publisher","unstructured":"Tsai ML, Tsai MK, Tsai YG, Lin YC, Hsu YL, Chen YT, et al. Montelukast Increased IL-25, IL-33, and TSLP via epigenetic regulation in airway epithelial cells. Int J Mol Sci. 2023;24(2). https:\/\/doi.org\/10.3390\/ijms24021227.","DOI":"10.3390\/ijms24021227"},{"issue":"5","key":"3381_CR61","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/febs.15750","volume":"289","author":"S Feng","year":"2022","unstructured":"Feng S, De Carvalho DD. Clinical advances in targeting epigenetics for cancer therapy. FEBS J. 2022;289(5):1214\u201339. https:\/\/doi.org\/10.1111\/febs.15750.","journal-title":"FEBS J"},{"issue":"10","key":"3381_CR62","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1038\/s41590-024-01932-8","volume":"25","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Naderi Yeganeh P, Zhang H, Wang SY, Li Z, Gu B, et al. Tumor editing suppresses innate and adaptive antitumor immunity and is reversed by inhibiting DNA methylation. Nat Immunol. 2024;25(10):1858\u201370. https:\/\/doi.org\/10.1038\/s41590-024-01932-8.","journal-title":"Nat Immunol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03381-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03381-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03381-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T17:38:40Z","timestamp":1746207520000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03381-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3381"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03381-z","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"assertion":[{"value":"20 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal procedures were approved by the Italian Ministry of Health (Authorization N. 785\/2020-PR, Prot. N. D9997.100). Obtainment of healthy donor-buffy coats was approved by Ethics Committee of the Istituto Superiore di Sanit\u00e0, Rome (prot. n\u00b0 OO-ISS 02\/10\/2019 0029604).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"137"}}